申请人:SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
公开号:EP0704446A1
公开(公告)日:1996-04-03
A novel β-lactam compound represented by general formula [1] and having an excellent antibacterial activity against gram-positive bacteria, in particular, methicillin-resistant staphylococci and methicillin-resistant coagulase-negative staphylococci, a pharmaceutically acceptable salt thereof, and a process for producing the same, wherein R¹ represents lower alkyl which may be hydroxylated; R² represents hydrogen or lower alkyl; X represents oxygen, sulfur or NH; Y represents nitrogen or carbon, provided n is 0 when Y represents nitrogen and n is 1 when Y represents carbon; and Z represents (each independently when n is 1) hydrogen, Ra (lower alkyl, etc.), A (aryl, etc.), -OH, -ORa, -OA, -SRa, -SA, -NH₂, -NHRa, -NRbRc (Rb and Rc being each lower alkyl, etc.), -NHA, -NRaA, -CONH₂, -CONHRa, -CONRbRa, -CONHA, -CONRaA, -CONHC(NH)NH₂, -COOH, -COORa, -COOA, -CORa, -COA, halogen, or cyano.
一种由通式[1]表示并对革兰氏阳性菌,特别是耐甲氧西林葡萄球菌和耐甲氧西林凝固酶阴性葡萄球菌具有优异抗菌活性的新型β-内酰胺化合物、其药学上可接受的盐及其生产工艺,其中R¹代表可羟基化的低级烷基;R² 代表氢或低级烷基; X 代表氧、硫或 NH; Y 代表氮或碳,条件是当 Y 代表氮时,n 为 0,当 Y 代表碳时,n 为 1;以及 Z 代表(当 n 为 1 时,各自独立地)氢、Ra(低级烷基等)、A(芳基等)、B(低级烷基等)、C(低级烷基等)和 D(低级烷基等)。Ra(低级烷基等)、A(芳基等)、-OH、-ORa、-OA、-SRa、-SA、-NH₂、-NHRa、-NRbRc(Rb 和 Rc 分别为低级烷基等)、-NHA、-NH₂。)、-NHA、-NRaA、-CONH₂、-CONHRa、-CONRbRa、-CONHA、-CONRaA、-CONHC(NH)NH₂、-COOH、-COORa、-COOA、-CORa、-COA、卤素或氰基。